Cytokinetics Inc at JMP Securities Life Science Conference Transcript
Let's go ahead and get started here. Thank you, everybody, again for being with us this morning at the 2019 JMP Securities life science conference.
Excited to have with us now Cytokinetics. Cytokinetics is a company that we have followed for many years, developing novel drugs focused on muscle biology. Lead program Omecamtiv in Phase 3 development for the treatment of heart failure. And there's a building now pipeline of follow-on compounds in cardiovascular medicine as well as the work you are doing in neuromuscular diseases.
So very happy to have the Company's CEO Robert Blum. Robert, thank you for being with us this morning and looking forward to the conversation.
Thank you, Jason. Thank you to those of you gathered here and also on the webcast. I will be making -- I will be presenting a few slides before we get into our conversation and I will be speaking about the Company as it is a pioneer and leader in the area of muscle biology. On this
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |